- $730.39m
- $513.08m
- $9.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.03 | ||
| Price to Tang. Book | 4.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 80.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -164.47% | ||
| Return on Equity | -194.63% | ||
| Operating Margin | -3382.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 14.02 | 9.04 | 1.29 | 17.47 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Directors
- Michael Rapp NEC (53)
- Purnanand Sarma PRE
- Corleen Roche CFO
- Sandra Stoneman GCN (48)
- Dennis Giesing OTH (68)
- Philip Wagenheim DRC (50)
- Richard Baron IND (65)
- John Lamattina IND (71)
- Michael Lefenfeld IND (40)
- Franklyn Prendergast IND (76)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 2nd, 2015
- Public Since
- October 2nd, 2020
- No. of Shareholders
- 63
- No. of Employees
- 118
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 87,011,822
- Address
- 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, 98011
- Web
- https://immunome.com/
- Phone
- +1 6103213700
- Auditors
- Ernst & Young LLP
Upcoming Events for IMNM
Immunome Inc Annual Shareholders Meeting
Immunome Inc Annual Shareholders Meeting
Q2 2025 Immunome Inc Earnings Release
Similar to IMNM
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Immunome share price?
As of Today at 21:15 UTC, shares in Immunome are trading at $8.40. This share price information is delayed by 15 minutes.
How has the Immunome share price performed this year?
Shares in Immunome last closed at $8.40 and the price had moved by -41.09% over the past 365 days. In terms of relative price strength the Immunome share price has underperformed the S&P500 Index by -45.63% over the past year.
What are the analyst and broker recommendations for Immunome?
The overall consensus recommendation for Immunome is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Immunome dividend yield?
Immunome does not currently pay a dividend.
Does Immunome pay a dividend?
Immunome does not currently pay a dividend.
When does Immunome next pay dividends?
Immunome does not currently pay a dividend.
How do I buy Immunome shares?
To buy shares in Immunome you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immunome?
As of the previous close price of $8.40, shares in Immunome had a market capitalisation of $730.39m.
Where are Immunome shares listed?
Here are the trading details for Immunome:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IMNM
What kind of share is Immunome?
Based on an overall assessment of its quality, value and momentum Immunome is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immunome share price forecast for 2025?
The analyst consensus target price for shares in Immunome is $23.67. That is 181.79% above the last closing price of $8.40.
Analysts covering Immunome currently have a consensus Earnings Per Share (EPS) forecast of -$2.77 for the next financial year.
Find out moreWhat is the trend in the Immunome share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immunome. Over the past six months, its share price has underperformed the S&P500 Index by -26.89%.
As of the last closing price of $8.40, shares in Immunome were trading -27.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immunome PE Ratio?
The Immunome PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immunome?
Immunome's management team is headed by:
- Michael Rapp - NEC
- Purnanand Sarma - PRE
- Corleen Roche - CFO
- Sandra Stoneman - GCN
- Dennis Giesing - OTH
- Philip Wagenheim - DRC
- Richard Baron - IND
- John Lamattina - IND
- Michael Lefenfeld - IND
- Franklyn Prendergast - IND